|
30 Oct 2022 |
Hinova Disclosed the Preclinical Results of HP518 (Oral AR PROTAC) at the 5th Annual TPD Summit
|
|
28 Oct 2022 |
Nuvalent Reports Preliminary Phase 1 Clinical Data from ARROS-1 Trial that Support Best-In-Class Potential of NVL-520 for Patients with ROS1-Positive NSCLC
|
|
28 Oct 2022 |
Sporos BioDiscovery Presents Preclinical Data on Differentiated TEAD Inhibitor Program, SPR1, at the 34th EORTC-NCI-AACR Symposium
|
|
28 Oct 2022 |
Edgewise Therapeutics Announces Initiation of LYNX Phase 2 Clinical Trial of EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (DMD)
|
|
27 Oct 2022 |
ESSA Pharma Presents Preclinical Data for its First Generation Androgen Receptor N-Terminal Domain Degrader at the 34th EORTC-NCI-AACR Symposium
|
|
27 Oct 2022 |
Corvus Pharmaceuticals Announces Initiation of Phase 1b/2 Clinical Trial of Ciforadenant as Potential First Line Treatment for Patients with Renal Cell Cancer
|
|
27 Oct 2022 |
Foghorn Therapeutics Announces New Data Demonstrating BRD9 Degradation in Patient Tumor Biopsies and Discloses New Selective CBP Program
|
|
26 Oct 2022 |
eFFECTOR Therapeutics Completes Enrollment in Second of Three Cohorts of Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID-19
|
|
26 Oct 2022 |
Boehringer Ingelheim enrolls first patient in Phase III trial of BI 1015550 in idiopathic pulmonary fibrosis
|
|
26 Oct 2022 |
Ascletis Announces U.S. IND Filing of Oral Antiviral ASC10 for Monkeypox Indication
|
|
26 Oct 2022 |
Orionis Biosciences Demonstrates Platform Capabilities of Genome-scale Molecular Glue Discovery and Rational Design at Targeted Protein Degradation Summit
|
|
26 Oct 2022 |
Biohaven Advances Development of the MoDE Platform Technology Licensed From Yale University
|
|
26 Oct 2022 |
Scorpion Therapeutics Presents Preclinical Proof-of-Concept Data for STX-721, a Next-Generation Exon 20 Mutant EGFR Inhibitor, at the EORTC-NCI-AACR Symposium 2022
|
|
26 Oct 2022 |
Camizestrant significantly improved progression-free survival vs. Faslodex in SERENA-2 Phase II trial in advanced ER-positive breast cancer
|
|
26 Oct 2022 |
Capivasertib plus Faslodex significantly improved progression-free survival vs. Faslodex in CAPItello-291 Phase III trial in advanced HR-positive breast cancer
|
|
24 Oct 2022 |
Positive Topline Data Announced from Mirum’s LIVMARLI Phase 3 MARCH Study in Progressive Familial Intrahepatic Cholestasis (PFIC)
|
|
24 Oct 2022 |
Quizartinib Granted Priority Review in the U.S. for Patients with Newly Diagnosed FLT3-ITD Positive Acute Myeloid Leukemia
|
|
24 Oct 2022 |
Novartis investigational oral monotherapy iptacopan demonstrates clinically meaningful superiority over anti-C5 treatment in Phase III APPLY-PNH study
|
|
23 Oct 2022 |
Merck’s PREVYMIS™ Demonstrates Efficacy in Phase 3 Study for Prevention of Cytomegalovirus Disease in Adults After Kidney Transplantation
|
|
21 Oct 2022 |
U.S. Food and Drug Administration (FDA) Accepts Supplemental New Drug Application for CAMZYOS® (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy to Reduce the Need for Septal Reduction Therapy
|
|
20 Oct 2022 |
STORM Therapeutics to present new data on its lead program STC-15 at the 34th EORTC-NCI-AACR Symposium and the 37th SITC Meeting
|
|
20 Oct 2022 |
Orionis Biosciences Secures $55 Million Financing to Support Advancement into Clinic
|
|
18 Oct 2022 |
Prelude Therapeutics Receives FDA Clearance of IND for PRT3789, a Potent and Selective First-in-Class SMARCA2 Protein Degrader
|
|
18 Oct 2022 |
Avilar Therapeutics to Present New In Vivo Proof-of-Concept Data for ATAC Extracellular Protein Degraders at Upcoming Drug Discovery Conferences
|
|
18 Oct 2022 |
PTC Provides Update on Ongoing Global PIVOT-HD Trial For PTC518
|
